This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma

This study has been completed.
Information provided by:
National Center for Research Resources (NCRR) Identifier:
First received: November 3, 2000
Last updated: June 23, 2005
Last verified: December 2003
When patients relapse after primary chemotherapy for Non-Hodgkin's lymphoma, they may be eligible to receive high-dose chemotherapy with autologous stem cell support. Unfortunately high-dose chemotherapy is curative in less than half the patients who receive it. This study is being conducted to determine the safety, side effects, and the ability to respond to an investigational vaccine that consists of tumor-pulsed dendritic cells given with an immune stimulating drug called interleukin-2. The patient must have a lymphomatous node accessible for excision to prepare the vaccine. Dendritic cells are immune cells that are obtained from the blood, and are important in the body's immune response to foreign substances. This study will examine the response of the immune system after three vaccinations (composed of dendritic cells, which have been exposed to dead fragments of lymphoma cells) given beginning three months after transplant. Vaccination may result in sensitizing the patient's dendritic cells to his lymphoma cells, potentially resulting in an immune response against the lymphoma. Twelve patients will be treated on study.

Condition Intervention Phase
Lymphoma, Non-Hodgkin Biological: tumor-pulsed dendritic cells Phase 3

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by National Center for Research Resources (NCRR):


Ages Eligible for Study:   10 Years to 70 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented, aggressive and/or intermediate grade NHL, B-cell and T-cell.
  • In relapse after first-line conventional chemotherapy. Primary therapy should include a doxorubicin-based regimen.
  • Patients must have disease sensitive to induction chemotherapy, radiation therapy, and/or radioimmunotherapy. Successful treatment of CNS or meningeal disease is allowed.
  • Patients must have accessible tumor for biopsy or excision.
  • Cumulative total doxorubicin: <500 mg/m2
  • Performance score 0-2
  • No prior pelvic RT
  • Patients with a prior malignancy are eligible if they were treated for cure and have no evidence of active disease.
  • Patients may not be taking immunosuppressive agents.
  • Informed Consent; IRB approval
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00006434

United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 48104-0914
Sponsors and Collaborators
National Center for Research Resources (NCRR)
  More Information Identifier: NCT00006434     History of Changes
Other Study ID Numbers: NCRR-M01RR00042-1694
M01RR000042 ( U.S. NIH Grant/Contract )
Study First Received: November 3, 2000
Last Updated: June 23, 2005

Keywords provided by National Center for Research Resources (NCRR):
Dendritic cells

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on August 18, 2017